| Filed On | Filing |
|---|---|
| 08 Oct 2026 |
8-K: Regulation FD Disclosure
On August 18, 2026, Haemonetics Corporation (the “Company”) furnished a Current Report on Form 8-K disclosing its entry into a non-exclusive supply agreement with CSL Plasma Inc. (“CSL”), under which CSL may utilize the Company’s NexSys ... |
| 18 Aug 2026 | 8-K: Regulation FD Disclosure |
| 12 Aug 2026 | SCHEDULE 13G/A |
| 06 Aug 2026 | S-8 |
| 06 Aug 2026 | 10-Q |
| 06 Aug 2026 | 8-K: Results of Operations and Financial Condition |
| 28 Jul 2026 |
Form 4: Madaus Martin D, Director
Received 2,538 shares as a grant or award |
| 28 Jul 2026 |
Form 4: Zane Ellen M, Director
Received 2,538 shares as a grant or award |
| 28 Jul 2026 |
Form 4: Pomeroy Claire, Director
Received 2,538 shares as a grant or award |
| 28 Jul 2026 |
Form 4: Kroll Mark W, Director
Received 2,538 shares as a grant or award |
| 28 Jul 2026 |
Form 4: Johnson Lloyd Emerson, Director
Received 2,538 shares as a grant or award |
| 28 Jul 2026 |
Form 4: Coyle Michael J, Director
Received 2,538 shares as a grant or award |
| 28 Jul 2026 |
Form 4: Bryant Diane M, Director
Received 2,538 shares as a grant or award |
| 28 Jul 2026 |
Form 4: Abernathy Robert E, Director
Received 2,538 shares as a grant or award |
| 28 Jul 2026 |
Form 3: Madaus Martin D, Director
No securities owned |
| 28 Jul 2026 | 8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders |
| 09 Jun 2026 | ARS |
| 09 Jun 2026 | DEFA14A |
| 09 Jun 2026 |
Proxy statement: annual meeting on July 24, 2026
CEO pay $12.0M, up 12% · say-on-pay vote |
| 08 Jun 2026 |
Form 4: Maunsell Farris Maryanne, VP, Chief Accounting Officer
Gave up 259 shares to cover exercise price or tax ($18.5K) |
Loading...
